This article is more than 5 years old. Information may no longer be current.
Top 10 leukemia studies from ASH 2013
Click Here to Manage Email Alerts
The 2013 American Society of Hematology Annual Meeting and Exposition in New Orleans highlighted new clinical research, novel treatment options, and guideline updates, as well as what to expect in emerging drug therapies. In particular, researchers presented several new, targeted therapies show promise to expand treatment options for various forms of leukemia.
Whether you missed the annual meeting and want to get an overview of the latest findings in leukemia research or need to recap the top leukemia abstracts from the annual meeting, this is your chance to evaluate your current approaches to leukemia and learn how new research and clinical updates can be translated into new patient care strategies.
1. Novel agent induced high response rate in high-risk CLL, SLL
The selective, small molecule Bcl-2 inhibitor ABT-199 showed antitumor activity in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Read more.
2. Obinutuzumab plus chlorambucil improved outcomes in untreated CLL
Obinutuzumab plus chlorambucil was associated with longer PFS, a higher complete response rate and a higher minimal residual disease negativity rate compared with rituximab plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia. Read more.
3. Anti-CD19 T cells show promise in adult, pediatric ALL
Engineered CTL019 cells underwent robust in vivo expansion and induced response in adult and pediatric patients with relapsed and refractory acute lymphoblastic leukemia. Read more.
4. Oral PI3K inhibitor demonstrates activity in CLL
IPI-145, a new oral, potent PI3K inhibitor, appeared well tolerated and showed clinical activity in patients with chronic lymphocytic leukemia, including those with relapsed or refractory disease. Read more.
5. Idelalisib plus rituximab extended survival in previously treated CLL
The addition of idelalisib to rituximab significantly extended survival in heavily pretreated patients with relapsed chronic lymphocytic leukemia, according to phase 3 study results. Read more.
6. CTL019 therapy induced response in CLL, ALL
Chimeric antigen receptor-expressing T cells that target CTL019 induced clinical response and long-term B-cell aplasia in patients with advanced, refractory and high-risk chronic lymphocytic leukemia, as well as adult and pediatric patients with relapsed, refractory pre-B-cell acute lymphoblastic leukemia. Read more.
7. Haploidentical HSCT graft manipulation prevented GVHD, improved survival in pediatric leukemia
Removing alpha- and beta-positive T cells and CD19-postive B cells from the donor graft reduced the risk for graft-versus-host disease and transplant-related mortality in children with acute leukemia undergoing HLA-haploidentical hematopoietic stem cell transplantation. Read more.
8. Anti-CD19 CAR-expressing T cells induce responses in lymphoma, leukemia
Matt Kalaycio, MD, director of the Bone Marrow Transplant Program at Taussig Cancer Institute at Cleveland Clinic, highlights study results that showed genetically modified T cells that express a chimeric antigen receptor to target the B-cell antigen CD19 yielded significant responses in patients with chemotherapy-refractory B-cell lymphomas, as well as acute lymphoblastic leukemia and acute myeloid leukemia. Read more.
9. Potential mechanism found for high TP53 mutation incidence in therapy-related AML, myelodysplastic disorder
Hematopoietic stem cells that acquire heterozygous TP53 mutations as a function of normal aging may be chosen in the presence of cytotoxic therapy in patients with therapy-related-acute myeloid leukemia and therapy-related-myelodysplastic syndrome. Read more.
10. Treatment regimens demonstrate promising activity in CLL
Ian W. Flinn, MD, PhD, of the Sarah Cannon Research Institute in Nashville, discusses results of a phase 3 study that showed the addition of idelalisib to rituximab significantly extended survival in heavily pretreated patients with relapsed chronic lymphocytic leukemia. Read more.